Martin Shkreli was "terminated as chief executive officer of the company and resigned from his position as a member of the board of directors" on December 17.
New York:
The controversial US pharma boss and hedge fund figure Martin Shkreli has been fired as CEO of KaloBios Pharmaceuticals following his arrest on fraud charges, the firm said Monday.
The news came on the heels of Shkreli's resignation Friday as boss of Turing Pharmaceuticals, the day after his indictment over allegations of a Ponzi scheme-like fraud conspiracy.
Shkreli was "terminated as chief executive officer of the company and resigned from his position as a member of the board of directors" on December 17, the day of his arrest, KaloBios said in a securities filing.
US Justice Department officials suspect the 32-year-old of mounting a brazen fraud between 2009 and 2014 at two hedge funds and another firm, prior to his career at either pharmaceutical company.
He is accused of lying to investors, moving money between investments to cover losses in other vehicles and siphoning off cash for personal expenses.
Shkreli, founder and CEO of Turing, rose to infamy earlier this year after he, bought rights to toxoplasmosis drug Daraprim and promptly raised the price from $13.50 a tablet to $750.
His tenure at KaloBios was particularly brief, as he had taken over as chief executive only on November 19.
In a Wall Street Journal interview, he said US authorities had been keen to arrest him.
"What do you do when you have the attention of millions of people? It seemed to me like it would be fun to experiment with," he said in reference to his posts on Twitter.
"What would it look like if I said something audacious or outrageous, even if I don't mean it literally, it'd be interesting to see how people would react.
"In retrospect, again, to be arrested over something that I don't think I should have been arrested over -- I did nothing wrong -- because of a social experiment and teasing people over the Internet, that seems like a real injustice," he stressed.
Shares of KaloBios have been suspended since Thursday, after falling more than 50 percent in pre-market trade on news of Shkreli's arrest that day.
The news came on the heels of Shkreli's resignation Friday as boss of Turing Pharmaceuticals, the day after his indictment over allegations of a Ponzi scheme-like fraud conspiracy.
Shkreli was "terminated as chief executive officer of the company and resigned from his position as a member of the board of directors" on December 17, the day of his arrest, KaloBios said in a securities filing.
US Justice Department officials suspect the 32-year-old of mounting a brazen fraud between 2009 and 2014 at two hedge funds and another firm, prior to his career at either pharmaceutical company.
He is accused of lying to investors, moving money between investments to cover losses in other vehicles and siphoning off cash for personal expenses.
Shkreli, founder and CEO of Turing, rose to infamy earlier this year after he, bought rights to toxoplasmosis drug Daraprim and promptly raised the price from $13.50 a tablet to $750.
His tenure at KaloBios was particularly brief, as he had taken over as chief executive only on November 19.
In a Wall Street Journal interview, he said US authorities had been keen to arrest him.
"What do you do when you have the attention of millions of people? It seemed to me like it would be fun to experiment with," he said in reference to his posts on Twitter.
"What would it look like if I said something audacious or outrageous, even if I don't mean it literally, it'd be interesting to see how people would react.
"In retrospect, again, to be arrested over something that I don't think I should have been arrested over -- I did nothing wrong -- because of a social experiment and teasing people over the Internet, that seems like a real injustice," he stressed.
Shares of KaloBios have been suspended since Thursday, after falling more than 50 percent in pre-market trade on news of Shkreli's arrest that day.
Track Latest News Live on NDTV.com and get news updates from India and around the world
